Last reviewed · How we verify

NCT06372613

Association Between LRG and Histologic Remission in Ulcerative Colitis

Recruiting now Last updated 22 August 2025
What this trial tests

trial in Ulcerative Colitis in Histologic Remission in 100 participants. Currently enrolling.

Timeline
25 February 2024
Primary endpoint
31 December 2025
31 December 2025

Quick facts

Lead sponsorShowa Inan General Hospital
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment100
Start date25 February 2024
Primary completion31 December 2025
Estimated completion31 December 2025
Sites1 location across Japan

Conditions studied

Sponsor

Showa Inan General Hospital

Who can join

Adults 20 to 90, any sex, with Ulcerative Colitis in Histologic Remission. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

We attempt to clarify the serum leucine-rich α 2-glycoprotein (LRG) level which can predict histologic remission in ulcerative colitis patients in this study. Colonoscopy with histology will be performed when histologic remission is predicted, irrespective of symptoms or serum LRG values. Serum LRG levels are analyzed by an enzyme-linked immunosorbent assay.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Showa Inan General Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06372613.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing